UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043226
Receipt number R000049327
Scientific Title Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2021
Date of disclosure of the study information 2021/04/01
Last modified on 2022/02/03 17:29:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2021

Acronym

Nationwide surveillance of bacterial pathogens isolated from children

Scientific Title

Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2021

Scientific Title:Acronym

Nationwide surveillance of bacterial pathogens isolated from children

Region

Japan


Condition

Condition

Respiratory tract infection

Classification by specialty

Infectious disease Pediatrics Child

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to analyze the antimicrobial susceptibilities of bacterial pathogens isolated from pediatric patient with respiratory tract infection though nationwide surveillance.

Basic objectives2

Others

Basic objectives -Others

Serotype distribution of H. influenzae and S. pneumoniae

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarhalis and Bordetella pertussis isolated from respiratory tract infection in children.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit

15 years-old >

Gender

Male and Female

Key inclusion criteria

H. influenzae, S. pneumoniae, M. catarrhalis and B. pertussis isolated from respiratory tract infection in children

Key exclusion criteria

None

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Naruhiko
Middle name
Last name Ishiwada

Organization

Medical Mycology Research Center, Chiba University

Division name

Department of Infectious Diseases

Zip code

260-8673

Address

260-8673

TEL

0432262799

Email

ishiwada@faculty.chiba-u.jp


Public contact

Name of contact person

1st name Naruhiko
Middle name
Last name Ishiwada

Organization

Medical Mycology Research Center, Chiba University

Division name

Department of Infectious Diseases

Zip code

260-8673

Address

1-8-1, Inohana, Chiba-shi, Chiba-ken, Japan

TEL

0432262799

Homepage URL


Email

ishiwada@faculty.chiba-u.jp


Sponsor or person

Institute

Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology

Institute

Department

Personal name



Funding Source

Organization

Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Chiba University

Address

1-8-1, Inohana, Chuo-ku Chiba-shi, Chiba-ken, Japan

Tel

0432262462

Email

inohana-shien@chiba-u.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2021 Year 01 Month 22 Day

Date of IRB

2021 Year 01 Month 22 Day

Anticipated trial start date

2021 Year 04 Month 01 Day

Last follow-up date

2024 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2021 Year 02 Month 02 Day

Last modified on

2022 Year 02 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049327


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name